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AbstrACt
Objectives Men who have sex with men (MSM) are at 
greater risk for human papillomavirus (HPV)-associated 
cancers. Since 2016, MSM have been offered the HPV 
vaccination, which is most effective when received prior to 
sexual debut, at genitourinary medicine clinics in the UK. In 
September 2019, the national HPV vaccination programme 
will be extended to boys. This study aimed to understand 
young MSM’s (YMSM) knowledge and attitudes towards 
HPV vaccination.
Design Questionnaires assessed YMSM demographics, 
sexual behaviour, culture, knowledge and attitudes 
towards HPV vaccination and stage of vaccine decision-
making using the precaution adoption process model. 
Focus groups explored sexual health information sources, 
attitudes, barriers and facilitators to vaccination and 
strategies to support vaccination uptake. Questionnaire 
data were analysed using descriptive statistics and focus 
group data were analysed thematically.
setting Questionnaires were completed online or on 
paper. Focus groups were conducted within Lesbian Gay 
Bisexual Transgender Queer organisational settings and a 
university student’s union in England and Northern Ireland.
Participants Seventeen YMSM (M=20.5 years) 
participated in four focus groups and 51 (M=21.1 years) 
completed questionnaires.
results Over half of YMSM were aware of HPV (54.9%), 
yet few (21.6%) had previously discussed vaccination with 
a healthcare professional (HCP). Thematic analyses found 
YMSM were willing to receive the HPV vaccine. Vaccination 
programmes requiring YMSM to request the vaccine, 
particularly prior to sexual orientation disclosure to family 
and friends, were viewed as unfeasible. Educational 
campaigns explaining vaccine benefits were indicated as a 
way to encourage uptake.
Conclusions This study suggests that to effectively 
implement HPV vaccination for YMSM, this population 
requires clearer information and greater discussion 
with their HCP. In support of the decision made by the 
Joint Committee on Vaccination and Immunisation, 
universal vaccination is the most feasible and equitable 
option. However, the absence of a catch-up programme 
will leave a significant number of YMSM at risk of HPV 
infection.
IntrODuCtIOn
Human papillomavirus (HPV), the most 
common sexually transmitted infection (STI) 
worldwide,1 has serious health consequences 
for men and women. HPV is recognised as a 
causative agent in cervical cancer, and is asso-
ciated with anogenital tumours, oropharyn-
geal cancers and genital warts.2 While boys 
and girls aged 12–13 years are vaccinated in 
school in Australia,3 4 the current UK strategy 
of vaccinating all girls aged 12–13 years does 
not protect young men who have sex with 
men (YMSM) against HPV infection and 
related diseases5 as they will not benefit from 
herd immunity.6 
A Joint Committee on Vaccination and 
Immunisation’s (JCVI) statement on MSM 
HPV vaccination7 in 2015 recommended 
that vaccination programmes be extended to 
MSM aged up to 45 years via genitourinary 
strengths and limitations of this study
 ► This is the first study in the UK to explore young 
men who have sex with men’s (YMSM) knowledge 
and attitudes towards human papillomavirus (HPV) 
vaccination. 
 ► Use of a theoretical model of behavioural change 
facilitates clear conceptualisation of health be-
havioural change and YMSM’s stage of HPV vaccine 
decision-making.
 ► The qualitative component obtained a diverse range 
of views of YMSM in England and Northern Ireland.
 ► Survey findings should be interpreted with caution 
due to the sample size.
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medicine (GUM) clinics. Mathematical modelling 
suggested that for MSM aged 40 or over, HPV vaccination 
in GUM clinics was likely to be an effective and cost-ef-
fective method of reducing HPV-related disease burden 
in MSM in England8 and elsewhere. Northern Ireland, 
Scotland and Wales are currently offering the HPV 
vaccine to MSM attending GUM clinics. Following a pilot 
programme in England9 which found suboptimal uptake 
(45%) and did not report completion rates, vaccination 
is now offered in GUM clinics. Hence, it is important to 
assess the reasons why MSM might not be willing to accept 
the vaccine through targeted HPV vaccination. An interim 
statement in July 2017 suggested that given the current 
high uptake in females, extending immunisation to all 
adolescent males is ‘highly unlikely to be cost-effective in 
the UK’ (p13).10 11 In July 2018, the JCVI recommended 
that the national HPV vaccination programme should be 
extended to include adolescent boys. It is planned that the 
programme, beginning in September 2019, will include 
boys aged 12/13 (England, school year 8; Northern 
Ireland, school year 9). Although some may now query 
the importance of the MSM programme (particularly 
for YMSM), this will still be valid for a number of years 
because the government have indicated that they will not 
initiate a catch-up programme for boys so there are still a 
significant number who will remain unprotected. Indeed, 
it is worth noting that it took 5 years of deliberation by the 
JCVI to make this decision and that boys aged 13 plus will 
not be offered the vaccine in schools.
The absence of a catch-up vaccination programme 
leaves many UK YMSM without funded access to the 
HPV vaccine before exposure to HPV.12 There is often a 
delay between the age of first sexual contact with another 
man and disclosure of sexual orientation to a healthcare 
professional (HCP),13 as a result, it is likely that MSM will 
have multiple sexual partners before attending a GUM 
clinic resulting in increased risk of HPV acquisition.14
A systematic review found that MSM HPV vaccine 
knowledge was low and MSM did not consider themselves 
at risk of infection, although over half would accept the 
vaccine if they were offered it.12 Most of these studies were 
conducted in North America (and none in the UK), with 
MSM over 26 years of age. Minimal attention has been 
given to the knowledge and attitudes towards HPV vacci-
nation among adolescent and YMSM (aged 16–24 years). 
This is an important area for research because MSM may 
acquire HPV at a young age, close to their sexual debut 
(the age of which is decreasing).14 This study aimed to 
examine the knowledge and attitudes of UK YMSM 
towards HPV vaccination to inform policy and practice 
recommendations for accessing this hard to reach group, 
supporting vaccination uptake and the optimisation of 
protection from HPV. Despite the changes to the vaccina-
tion programme made since this research was conducted 
in 2017, in the absence of a catch-up programme, the 
newly implemented universal programme will cover not 
all YMSM. Therefore, understanding YMSM knowledge 
and attitudes to HPV remains relevant in the UK. Our 
findings are also relevant for guiding other programmes 
internationally that do not have a gender-neutral 
programme and are considering implementation of a 
programme for YMSM.
MethODs
study design
We conducted questionnaires and focus groups with 
YMSM aged 16–24 years. The two substudies are described 
separately below.
Questionnaire study
Data collection
The survey was administered online using Survey Monkey 
and on paper and advertised via various Lesbian Gay 
Bisexual Transgender Queer (LGBTQ) organisations on 
social media (Twitter and Facebook). We have combined 
both the online and pen and paper completions for this 
paper.
Measures
The questionnaires (online supplementary material A) 
assessed demographics (adapted from Hickson et al)15; 
sexual behaviour (adapted from Sadlier et al)16; culture 
(adapted from Zou et al)17 and HPV vaccine stage of 
decision-making using the precaution adoption process 
model (PAPM).18 The PAPM has six stages of behavioural 
change decision-making and has been used to examine 
knowledge and attitudes to HPV vaccination.19 Those who 
indicated awareness of the HPV vaccine were asked to 
complete validated HPV knowledge/attitudes scales.20 21
Patient and public involvement
The HPV knowledge/attitude questionnaire scales were 
adapted for use with MSM through consultation with an 
expert panel including a key stakeholder group (The 
Rainbow Project (TRP)) and MSM focus groups.
YMSM were not involved in the development of the 
qualitative component of this study, however, staff from 
TRP helped develop the study design and documentation.
The findings will be disseminated to YMSM via social 
media and TRP.
Focus group study
Data collection
We aimed to achieve data saturation22 by recruiting 8–10 
YMSM per focus group with a mix of social background, 
age, ethnicity and religion. YMSM were defined through 
self-identification as male (including transgender male), 
at or over the age of sexual consent, sexually attracted 
to men or had sex with a man.14 Age inclusion criteria 
were based on WHO’s definition of ‘young’: 15–24 years. 
A minimum of 16 years was specified as it is the age of 
sexual consent in the UK.
For the focus groups, potential participants were 
provided with written study information, and asked to 
register their interest at local LGBTQ organisations, 
university information days, university student union 
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clubs and societies, and secondary school LGBTQ groups. 
Organisations advertised the study through social media 
and snowball sampling was employed.
CF conducted the focus groups within LGBTQ organi-
sational settings and a university student’s union building.
Prior to the focus groups, participants were asked to 
complete the questionnaire (described in the Question-
naire study section).
The focus group topic guide (online supplementary 
material B) was applied flexibly to allow for emergent 
issues and began by exploring sources of sexual health 
information and advice before engaging in sexual activity 
(not presented here). Perceptions of HPV risk in relation 
to six other STI’s were then discussed using a sorting task 
in which a list of STIs were ordered by what is least to 
most concerning (findings not reported here). Attitudes 
towards HPV vaccine, barriers and facilitators to vaccina-
tion and possible intervention strategies to support vacci-
nation uptake were explored. Experiences of disclosing 
sexual orientation to HCP were also discussed. All partic-
ipants were informed that the HPV vaccine was most 
protective if received prior to first sexual encounter. 
Participants were asked to reflect as to how they would 
have viewed taking the vaccine when they were 12–13 
years.
Analysis
Questionnaire study
Questionnaire data were inputted to SPSS V.12 and 
analysed descriptively with frequencies and proportions 
reported for categorical data and mean and standard 
deviation for continuous data. Due to a lack of statistical 
power, it was not possible to use inferential statistics for 
analysis. Participants’ PAPM vaccine decision-making 
stage was classified into six stages: unaware, unengaged, 
undecided, decided not to vaccinate, decided to vaccinate 
and those who had already been vaccinated.19 If partic-
ipants indicated they were not sexually active they were 
asked to skip the sexual contact questions. If they indi-
cated that they had never heard of the HPV vaccine they 
did not complete the knowledge/attitude scores. Knowl-
edge and attitudes held by participants about HPV and 
HPV vaccination were analysed using descriptive statistics.
Focus group study
Focus groups were audio recorded, transcribed verbatim, 
anonymised and analysed thematically23 using QSR NVivo 
(V.10.0). This approach was chosen because it offers a 
clear analysis process while remaining flexible.23 JMK 
and CF independently coded the first transcript system-
atically, line-by-line, compared their coding and reached 
consensus on the definition of codes. These initial codes, 
which captured features of interest in the data, were then 
applied to the remaining transcripts. The content of all 
the codes was read and compared with each other to itera-
tively refine and cluster codes into themes and subthemes. 
For example, duplicate codes with synonymous meanings 
were collapsed. A description of each theme capturing 
instances of divergence was then written by JMK. At each 
stage, findings were verified and discussed by the research 
team to assess the accuracy and credibility of the interpre-
tation, promote inter-rater reliability and ensure rigour.
 Participants were not provided any financial remuner-
ation for their time.
results
Participant characteristics
Between September 2016 and March 2018, questionnaires 
were completed by 51 YMSM. From this 51, four focus 
groups in Northern Ireland (n=3) and England (n=1) 
were conducted between September and December 2016 
with 17 YMSM who had completed the questionnaires 
(table 1). Focus group size ranged from two to six partici-
pants and lasted approximately 45 min.
Questionnaire results
The majority (n=49) were sexually active and reported 
both oral and anal intercourse in the past 12 months 
(n=35), a wide range of partner numbers (M=5 partners, 
range 0–25), and ‘sometimes’ (n=17) or ‘never’ (n=16) 
used condoms. Twenty-nine (57%) participants had 
accessed sexual health services (table 2).
Nineteen participants (37%) had never heard of HPV 
and did not complete the rest of the questionnaire. Of 
those who had heard of HPV in accordance with the 
PAPM, 18% were in the ‘decided to act’ stage of vaccine 
decision-making (stage 5), none had decided that they 
did not want the vaccine (stage 4) and 22% had already 
been vaccinated (stage 6) (table 3).
Of those who were aware of HPV (n=28), knowledge of 
HPV and the HPV vaccine was generally high; mean items 
correct 65% (M=13.3, SD 4.7) and 60% (M=3.3, SD, 1.2), 
respectively. However, there was a wide variation in knowl-
edge scores (HPV range, 3–20; HPV vaccine range, 0–5) 
(table 3). Participants were aware that HPV affected men, 
the method of HPV transmission, and that vaccination 
was most effective if given prior to sexual debut. However, 
awareness of the link between HPV and genital warts and 
the severity of an HPV infection was lower as the majority 
of YMSM thought HPV infection always required treat-
ment and that infection with HPV would always lead to 
health problems (table 3).
Thirty-three participants (65%) reported that HPV 
vaccination had never been discussed with or recom-
mended by an HCP (table 3). The mean age participants 
were willing to disclose their sexuality to an HCP was 
18.3 years (range=11–23, SD=2.40) (table 3). The most 
comfortable setting cited to receive the HPV vaccine was 
primary care or LGBTQ-specific services, rather than 
GUM clinics (table 3).
Qualitative results
Two main themes and several subthemes were elicited 
from the thematic analysis: (1) Willingness to be vacci-
nated and (2) Implementation recommendations. 
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Anonymous quotes illustrating the key themes are 
presented below. Minimal differences in attitudes towards 
HPV between geographical settings were found.
Willingness to be vaccinated
Despite a perceived lack of knowledge about HPV and 
the vaccine and the threat posed to men, most partici-
pants were willing to receive the vaccine and wanted 
more information.
P1: I only knew about it because of the cervical cancer 
(…)
P2: I didn’t even know that was what it was for.
P1: I didn’t know even if like that would apply to us, 
so I don’t even know what the dangers are.
Focus group 2
Participants were motivated to receive the vaccine to 
protect their health and a small number of participants 
suggested that the cost and number of doses of the 
vaccine were not barriers to vaccination.
I’m not going to say like get rid of worry because you 
still have to…it’s your sexual health, but it would be 
safer in a sense (…) I’m better protected – I think 
would be a better way of putting it. So, I think my own 
health would encourage me more [to ask or accept 
the HPV vaccine]. I’d rather be protected than not 
protected.
Focus group 3, unidentifiable speaker
Implementation recommendations
Across the focus groups, recommendations to support 
the implementation of the HPV vaccine were gathered 
and grouped into two subthemes: ‘promoting and raising 
awareness of the vaccine’ and ‘identifying and offering 
YMSM the HPV vaccination’.
Promoting and raising awareness of the vaccine
Better understanding of the benefits and side effects of the 
vaccine were expected to encourage uptake. To promote 
the vaccine and inform YMSM, awareness campaigns and 
advertisements on the internet, radio, television, social 
media, in University society’s, LGBTQ youth groups and 
dating apps were suggested.
For this generation particularly, social media and TV 
ads and newspapers – well, probably not newspapers, 
but radio ads as well. You know, a campaign around 
getting people vaccinated, I think that would be very 
beneficial for young people these days.
Focus group 3, unidentifiable speaker
Table 1 Participant characteristics
Participant characteristics
Questionnaire participants
Focus group participants (subset of 
questionnaire participants)
M (SD) Range N M (SD) Range
N (% of 
sample)
Age (years) 21.06 (2.6) 16–24 20.5 (2.73) 16–24 18* (100)
Ethnicity 
  White 44 (86.3) 15 (83.3)
  Other 6 (11.8) 3 (16.6)
  Missing 1 (1.9)
Location 
  Northern Ireland 36 13 (72.2)
  England 15 5 (27.8)
Education 
  Full-time education 26 11
  Employed full time 17 4
  Employed part time 5 1
  Unemployed 2 1
  Missing 1 1
Group size 
  Focus group 1* 6
  Focus group 2 2
  Focus group 3 4
  Focus group 4 5
*One participant completed the questionnaire and left before the focus group began due to time constraints.
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Participants suggested including information about the 
vaccine for YMSM in primary care and the sexual health 
education curriculum in schools. Indeed, it was noted 
that there is a lack of MSM-specific sexual health and rela-
tionship information provided in the latter.
When you’re receiving that [heterosexual relation-
ship education] in school, (…) it just reinforces the 
fact that you’re (…) not relating to it means that 
you’re not normal like everyone else, so you don’t 
want to speak about it. So it would just be better if 
it [HPV vaccine education for MSM] was just part of 
that education anyway.
Focus Group 2, participant 1
Table 2 Sexual contact and relationships
Sexual contact and 
relationships M (SD) Range N (%)
Have you ever in the past had sex with a man or do you plan to in 
the future?
  Yes 49 (96.08)
  No 1 (1.96)
  Missing 1 (1.96)
Relationship status 
  Single 26 (50.98)
  In a relationship 21 (41.18)
  Cohabiting 2 (3.92)
  Civil partnership 1 (1.96)
  Missing 1 (1.96)
Are you sexually active?
  Yes 38 (74.51)
  No 8 (15.69)
  Missing 5 (9.8)
How many male sexual partners 
have you had in the past 
12 months?
5 (6) 0–25
What type of intercourse have you had in the past 12 months?
  Oral only 3 (5.88)
  Anal only 2 (3.92) 
  Both oral and anal 35 (68.63)
  Neither 3 (5.88)
  Missing 8 (15.69)
In the past 12 months have you used condoms?
  Always 9 (17.65)
  Sometimes 17 (33.33)
  Never 16 (31.37)
  Prefer not to say 1 (1.96)
  Missing 8 (15.69)
Do you access sexual health 
services?
  Yes 29 (56.86)
  No 14 (27.45)
  Missing 8 (15.69)
Table 3 HPV vaccine: culture, awareness and stage of 
decision-making
M (SD) Range N
GP aware of sexuality
  Yes 22 (43.14%)
  No 17 (33.33%)
  Not sure 8 (15.69%)
  Missing 4 (7.84%)
Willing to disclose MSM status to HCP 
to receive HPV vaccine?
  Yes 41 (80.39%)
  No 3 (5.88%)
  Not sure 3 (5.88%)
  Missing 4 (7.84%)
  If yes, at what age? 18.3 (2.4) 11–23
Has an HCP ever recommended an HPV vaccine to you?
  Yes 11 (21.57%)
  No 33 (64.71%)
  Not sure 1 (1.96%)
  Missing 6 (11.76%)
Discussed HPV vaccination with HCP 
  Yes 10 (19.61%)
  No 34 (66.67%)
  Missing 7 (13.73%)
Most comfortable setting to receive HPV vaccine(some ticked 
more than one option)
  Genitourinary medicine 17 (33.33%) 
  Primary care 30 (58.82%) 
  Lesbian gay bisexual 33 (64.71%) 
  Transgender 
organisations
1 (1.96%) 
  Non-LGBTQ-specific 
sexual health provider 
2 (3.92%) 
  HIV clinic 1 (1.96%) 
Prior awareness of HPV
  Yes 28 (54.9%)
  No 19 (37.25%)
  Missing 4 (7.84%)
PAPM (stage of vaccine decision-making)
  Stage 2 unengaged: 
I have never thought 
about vaccination 
against HPV
17 (33.33%)
  Stage 3 undecided: I 
am undecided about 
vaccination against 
HPV
2 (3.92%) 
  Stage 4 decided not 
to act: I have decided 
and do not want to 
vaccinate myself 
against HPV
0
Continued
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Identifying and offering YMSM the HPV vaccination
The ideal pre-exposure timing for vaccination and the 
fluid, undefined nature of sexual preferences at a young 
age were perceived as barriers to identifying eligible 
recipients. There were mixed feelings about whether it 
would be acceptable for HCPs to ask boys (<16 years) to 
disclose their sexuality for this purpose due to concern 
about parents being informed and a lack of a trusting 
relationship. It was, however, also noted that questions 
about sexuality need to be normalised, particularly in 
primary care.
Interviewer: If everybody was getting the HPV 
vaccine…
Participant 2: That’s probably what they should do, 
because, I mean, (…) someone might think now, oh, 
I’ll never have sex with a man, but then, later down 
the line, they might do.
Focus group 4
The focus group participants wanted the benefits 
of vaccination to be explained and for the vaccine to 
be offered in a natural, relaxed manner, opportunis-
tically, rather than having to request it. Participants 
felt that they would be unlikely to request the vaccine 
because they would need more knowledge and they felt 
too uncomfortable.
Participant 2: As long as there was someone profes-
sional telling me what’s it about, what’s it going to do, 
and what it could do if it goes wrong.
Focus group 2
Participants reckoned it was not feasible to expect 
young boys to identify themselves for the HPV vaccine 
when they potentially had not disclosed or decided their 
sexual orientation. There was also a preference for not 
singling boys out by their sexuality when offering the 
vaccine. Similarly, receiving the vaccine confidentially was 
important because the potential for bullying and embar-
rassment would act as barriers. It was noted by participants 
that universal vaccination of all boys would avoid these 
problems. A young person seeking sexual health advice 
represented an opportunity to identify eligible boys. 
However, this is likely to occur post sexual encounter—
after the risk of exposure to the virus.
I would want them to approach me. I wouldn’t go out 
of my way to go and get it.
Focus group 3, unidentifiable speaker
Interviewer: So then you’re asking Year 8 and 9 that 
age group (…) -
Unidentifiable participant: To basically out 
themselves…
[Agreement] Interviewer: Do you see that as being a 
feasible scenario?
Unidentifiable participant: No.
Unidentifiable participant: Absolutely not.
Unidentifiable participant: The only kind of way 
round that is if every like male child is also vaccinat-
ed, but (…) obviously they won’t do that because in 
terms of cost of vaccines.
Focus group 3, unidentifiable speaker
Participant 2: When you get your vaccinations in 
school, you all, (…) used to go in to get your vaccina-
tions [as a class]. If it were like that, I wouldn’t do it, 
because I wouldn’t like anyone seeing.
Focus group 4
Participant 6: Why wouldn’t it be offered to like 
young males in school, (…) so it was like before like 
presumably anybody had had sex (…). A lot more 
people would get it that way.
Focus group 1
There were mixed feelings about general practitioners 
(GPs) or specialist sexual HCPs offering the vaccine. The 
relationship with the HCP was important; if YMSM have 
a good relationship with their GP then being offered the 
HPV vaccine by them is preferable. In contrast, a small 
number would feel more comfortable being offered the 
vaccine by someone they trust from a community LGBTQ 
group or local sexual health centre. A comment was also 
made about the nature of the vaccine being related to 
sexual health meaning it made more sense/was easier 
to offer it via specialist services. However, prior to disclo-
sure or sexual activity, the participants commented that 
boys may not engage with or know about sexual health 
or LGBTQ organisations so offering the vaccine in these 
settings may represent a barrier.
Telling your family GP you’re gay before you’ve told 
your family would be a big no I think because the GP 
might go back and tell your parents and then out you.
M (SD) Range N
  Stage 5 decided to act: 
I have decided and I do 
want to vaccinate
9 (17.65%) 
  myself against HPV
  Stage 6 acted: I 
have already been 
vaccinated against HPV
11 (21.57%) 
  Missing 12 (23.53%) 
Knowledge scores
  HPV knowledge score 
(max 20)
13.3 (4.7) 3–20 27
  HPV vaccination 
knowledge score (max 
5)
3.3 (1.2) 0–5 27
GP, general practitioner; HCP, healthcare professional; HPV, 
human papillomavirus; LGBTQ, Lesbian Gay Bisexual Trans 
Queer; MSM, men who have sex with men; PAPM, precaution 
adoption process model 
Table 3 Continued 
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Focus group 3, unidentifiable speaker
If you have to go and ask about it and ask for it, 
who would you ask because you wouldn’t be able to 
come here [Community LGBTQ group] because you 
wouldn’t know here existed.
Focus group 4
Written invitations from GPs offering the vaccine to 
eligible patients were also suggested. However, this would 
require boys to identify as MSM when registering or being 
asked about their sexuality by an HCP. A small number of 
accounts suggested that it would be acceptable to refer 
patients to receive the HPV vaccine in sexual health 
clinics if it was not available in a GP setting. Offering the 
vaccine in schools when YMSM are beginning to have 
their first sexual encounters was suggested. Similarly, the 
school nurse was a trusted individual for some and there-
fore may be an acceptable person to provide the vaccine.
DIsCussIOn
This is the first study to examine the views of YMSM 
towards the HPV vaccine in the UK. Despite being sexu-
ally active and willing to disclose sexual orientation to 
receive the vaccine, most participants had never been 
recommended the HPV vaccine, suggesting that MSM are 
not being offered the vaccine at the most opportune time. 
The data also suggested that HPV knowledge in YMSM 
is low, with almost half of participants being unaware of 
HPV or the vaccine. YMSM were willing to receive the 
vaccine but wanted additional information about HPV 
and the vaccine. Given the reluctance to disclose informa-
tion about sexuality to HCPs (prior to disclosure to signif-
icant others), the wide range of sexual partner numbers, 
and lack of consistent contraceptive use, combined with 
the importance of supporting vaccination prior to poten-
tial exposure, the findings highlight significant barriers 
to MSM accessing the vaccine. Early provision of informa-
tion was recommended through awareness campaigns, 
advertisements and the school health education 
curriculum. However, even with enhanced awareness, 
programmes that rely on YMSM to present for vaccina-
tion (particularly prior to sexual orientation disclosure) 
were not viewed as feasible. Furthermore, preferences for 
GPs or specialist HCPs offering the vaccine were depen-
dent on the relationship with the HCP. Offering the 
vaccine to MSM in schools was thought to be acceptable. 
We accept that many of these issues will now hopefully be 
addressed by the extension of the current female vaccina-
tion programme to boys in September 2019, although the 
lack of catch-up programme for boys would indicate that 
there is still a need for the vaccine programme to target 
YMSM for at least the next 6 years as a significant number 
of YMSM will be a risk of HPV infection. In addition, 
these findings offer insights into barriers to vaccination 
for YMSM which will be useful if the uptake of a universal 
vaccination programme is low.
strengths and limitations
This is the first study in the UK exploring this topic 
with YMSM. By conducting this research in more than 
one setting, we can comment on the transferability of 
our findings; we found minimal differences in attitudes 
towards HPV between settings. The use of a theoretical 
model of behavioural change, the PAPM, also facilitates 
clear conceptualisation of health behavioural change and 
YMSM’s stage of HPV vaccine decision-making.
We aimed to continue data collection until saturation, 
however, recruitment difficulties and the study time frame 
meant that the decision to cease recruitment was prag-
matic. The sensitivity of the topic, the hard to reach 
population and the lack of monetary compensation for 
the participant’s time are possible explanations for this. 
Therefore, the findings must be read with caution. Those 
who self-selected to participate may be more comfortable 
with their sexuality than those who did not agree. Indeed, 
recruiting through LGBTQ organisations narrowed our 
participant pool to those engaged with these services who 
had disclosed their sexual orientation. The small sample 
size for the quantitative data resulted in a lack of statis-
tical power to analyse data using inferential statistics and 
should be considered in generalising beyond the study 
sample. Small sample size in research with sexual and 
gender minorities is a recognised limitation.24 The inter-
view sample age range of 16–24 years is older than the 
target population for the vaccine—12–13 years. Although 
the participants were asked to consider how they would 
view the vaccine and strategies to implement it among 
YMSM, it is unclear whether current YMSM share similar 
attitudes.
Implications for research and practice
The reluctance of YMSM to discuss their sexuality with 
HCPs before they have disclosed to significant others 
has important implications for the success of an HPV 
vaccination programme. Previous research shows that 
MSM disclosing their sexuality to significant others, 
visiting HCPs in the past year and previous STI diag-
nosis predict disclosure to an HCP.25 In the absence of 
a catch-up programme for boys, additional measures to 
support YMSM to access the vaccine are necessary. For 
instance, information may need to be provided to young 
men outside of healthcare settings including educa-
tional contexts during sex and relationship education 
or HCPs may need to take an active role in opportunis-
tically providing information during consultations for 
non-sexual health related matters. To support the latter, 
GPs and other HCPs may require additional education 
and training.26 27
Comparison to existing literature
A lack of knowledge does not appear to deter MSM will-
ingness to be vaccinated.28 However, MSM in this study 
and in others28 desired more information. Poor knowl-
edge of the HPV vaccine among YMSM has also been 
reported previously.12 29
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Other qualitative work with MSM has shown support 
for vaccinating all adolescent boys in school in part to 
protect against stigma arising from vaccination policies 
targeting MSM.30 This would also remove the barrier of 
MSM having to request the vaccination, especially prior 
to sexual debut.27
Our finding that MSM are unlikely to disclose sexual 
orientation to a HCP prior to sexual debut, has been 
reported elsewhere,13 suggesting that HPV vaccine 
programmes delivered by HCPs would be of ‘limited 
benefit’.13 Participants in our study recommended 
that the vaccine is offered by HCPs rather than expecting 
them to request it; however it is unclear whether initial 
reluctance to disclose sexuality would prevent vaccina-
tion uptake. The absence of an HCP’s recommendation 
has previously been identified as a barrier to vaccina-
tion.31 A new National Health Service England standard 
recommending ‘sexual orientation monitoring’ whereby 
patients aged 16 and over are asked to disclose their 
sexual orientation at every face-to-face appointment may 
help to identify those eligible for vaccination.32 Although 
this standard would not help identify those younger than 
16 years who may benefit from the vaccine.
Previous research has found that most MSM have posi-
tive attitudes towards vaccinations against STIs and would 
be willing to receive the HPV vaccine.29 30 However, indi-
vidual and systemic barriers such as access to sexual health 
clinics, disclosure of sexual orientation, concern about 
confidentiality or belief that HPV vaccine is not effective 
after sexual debut, may compromise the effectiveness of 
vaccination strategies.30 Additionally, perceptions that 
HPV is relatively uncommon and harmless may lead to 
low desirability of the vaccine resulting in suboptimal 
coverage and therefore reduced cost-effectiveness.30
In line with our findings, awareness-raising strategies 
are vital to HPV vaccination programme success.29 33–35 
To raise awareness and motivate vaccine uptake, a public 
health campaign may be necessary.28 When developing 
strategies for HPV vaccination programmes, stakeholders 
can learn from the introduction of vaccinations such as 
hepatitis B and should engage with the target population 
and coordinate between stakeholders to ensure consis-
tent messages.33 In addition, offering the HPV vaccina-
tion to MSM alongside other vaccinations and during STI 
screening consultations has been recommended.29 35
COnClusIOns
This study suggests that UK YMSM’s are willing to receive 
the HPV vaccine. However, the UK’s current HPV vaccine 
programme that relies on MSM to present for vaccina-
tion (particularly prior to sexual orientation disclosure) 
was not viewed as feasible. The importance of supporting 
vaccination prior to potential virus exposure combined 
with the reluctance to disclose information about sexual 
orientation means personal knowledge and awareness of 
the HPV vaccine is important, therefore, early provision 
of information is recommended. Offering the vaccine 
in healthcare and education settings may be accept-
able, although the barriers to this channel of provision 
may mean that, in support of the decision made by 
the JCVI, universal vaccination is the most feasible and 
equitable option. However, in the absence of a catch-up 
programme, there is still a need for the UK vaccine 
programme to target YMSM as a significant number will 
remain at risk of HPV infection. These findings also help 
guide other programmes internationally that do not have 
a gender-neutral programme and are considering imple-
mentation of a programme for YMSM.
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